- Home
- NECB vs FHTX Comparison
NECB vs FHTX Comparison
Compare NECB & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- FHTX
- Stock Information
- Founded
- NECB 1934
- FHTX 2015
- Country
- NECB United States
- FHTX United States
- Employees
- NECB N/A
- FHTX N/A
- Industry
- NECB Savings Institutions
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NECB Finance
- FHTX Health Care
- Exchange
- NECB Nasdaq
- FHTX Nasdaq
- Market Cap
- NECB 281.2M
- FHTX 271.5M
- IPO Year
- NECB N/A
- FHTX 2020
- Fundamental
- Price
- NECB $21.15
- FHTX $5.37
- Analyst Decision
- NECB
- FHTX Strong Buy
- Analyst Count
- NECB 0
- FHTX 8
- Target Price
- NECB N/A
- FHTX $12.63
- AVG Volume (30 Days)
- NECB 31.2K
- FHTX 110.9K
- Earning Date
- NECB 07-24-2025
- FHTX 08-07-2025
- Dividend Yield
- NECB 3.79%
- FHTX N/A
- EPS Growth
- NECB N/A
- FHTX N/A
- EPS
- NECB 3.29
- FHTX N/A
- Revenue
- NECB $103,145,000.00
- FHTX $23,504,000.00
- Revenue This Year
- NECB $1.90
- FHTX $33.60
- Revenue Next Year
- NECB $6.93
- FHTX $5.87
- P/E Ratio
- NECB $6.41
- FHTX N/A
- Revenue Growth
- NECB N/A
- FHTX N/A
- 52 Week Low
- NECB $19.75
- FHTX $2.95
- 52 Week High
- NECB $31.72
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NECB 31.34
- FHTX 47.40
- Support Level
- NECB $22.94
- FHTX $6.00
- Resistance Level
- NECB $22.67
- FHTX $6.79
- Average True Range (ATR)
- NECB 0.63
- FHTX 0.43
- MACD
- NECB -0.28
- FHTX -0.06
- Stochastic Oscillator
- NECB 2.35
- FHTX 13.10
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.